Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

Revenues for BIOCON are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 41.827625
debtToEquity 50.024000
earningsGrowth 4.095000
revenueGrowth 0.092000
grossMargins 0.608710
operatingMargins 0.076250
trailingEps 4.880000
forwardEps 9.179340

BIOCON's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights BIOCON's potential for increased earnings and a stronger financial performance in the upcoming year.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

BIOCON's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


The recent buy bias from analysts suggests BIOCON is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, BIOCON appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.